Projection of Stroke Incidence and Costs in China: 2022 to 2050
Projektion der Schlaganfallinzidenz und -kosten in China: 2022 bis 2050
Stroke · 2026-10 · 57 (10) · 3081-3090
DOI: 10.1161/strokeaha.125.054522 ↗Auf einen Blick
Für China werden bis 2050 steigende Schlaganfallinzidenz und -kosten prognostiziert. Haupttreiber sind ischämische Schlaganfälle und die Alterung der Bevölkerung.
Fragestellung
Wie entwickeln sich Schlaganfallinzidenz und -kosten in China von 2022 bis 2050?
Methode
Projektion auf Basis von GBD-2021-Daten; jährliche alters- und geschlechtsspezifische Inzidenzen von 2022 bis 2050, kombiniert mit Bevölkerungsprognosen; deterministisches Entscheidungsbaum-Modell; Sensitivitätsanalysen.
Ergebnisse
Gesamtinzidenz von 4,35 Millionen (95 % UI 3,09–5,89) 2022 auf 9,59 Millionen (95 % UI 6,81–13,01) 2050. Hospitalisierungskosten von $46,1 Milliarden (95 % UI 44,94–47,24) auf $91,2 Milliarden (95 % UI 89,28–93,13).
Schlussfolgerung der Autor:innen
Schlaganfallinzidenz und -kosten in China werden bis 2050 ansteigen, vor allem durch ischämischen Schlaganfall und Bevölkerungsalterung.
Kernaussagen
- Gesamtinzidenz: 4,35 Millionen 2022; 9,59 Millionen 2050
- Hospitalisierungskosten: $46,1 Milliarden 2022; $91,2 Milliarden 2050
- Kosten konzentrieren sich zunehmend bei Erwachsenen ab 65 Jahren
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Stroke, 2026-10. Verfasst von Yutong Jiang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Policy and Management, Nanjing Medical University, China (Y.J., M.X., M.C.). Hauptthemen laut MEDLINE: Stroke, Health Care Costs, Cost of Illness. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: Stroke imposes a substantial and growing health and economic burden in China, yet forward-looking estimates of stroke-related costs remain scarce. METHODS: Annual age- and sex-specific incidence rates of ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage were projected from 2022 to 2050 using 2021 as the baseline year. Baseline incidence estimates were obtained from the Global Burden of Disease 2021 database, and future trends were projected using an exponential growth model parameterized by the average annual percent change estimated from 1990 to 2021 Global Burden of Disease data. Projected incidence rates were combined with China-specific population projections. A deterministic decision-tree model was used to estimate hospitalization costs, direct medical costs, and societal costs over a 12-month time horizon in China, using probabilities and unit costs from published literature. We used uncertainty intervals (UI) to quantify the plausible range of all projected outcomes. One-way sensitivity analyses were conducted to assess uncertainty in epidemiological and cost parameters. RESULTS: Total incident strokes are projected to increase from 4.35 million (95% UI, 3.09–5.89 million) in 2022 to 9.59 million (95% UI, 6.81–13.01 million) in 2050. By 2050, ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage incidences are projected to reach 7.89, 1.59, and 0.11 million, respectively. Total annual stroke hospitalization costs are projected to rise from $46.1 billion (95% UI, 44.94–47.24 billion) in 2022 to $91.2 billion (95% UI, 89.28–93.13 billion) in 2050; direct medical costs and societal costs are projected to increase from $67.6 billion to $133.9 billion and from $145.6 billion to $288.4 billion, respectively. Costs will be increasingly concentrated among adults aged ≥65 years, especially those aged ≥85 years. In 2050, stroke costs among men are projected to be approximately 1.3 times those for women. In sensitivity analyses incorporating incidence uncertainty, total annual hospitalization costs ranged from $39.9–$62.3 billion in 2022 to $65.0–$123.6 billion in 2050. CONCLUSIONS: Stroke incidence and costs in China are projected to increase through 2050, driven primarily by ischemic stroke and population aging, highlighting the need for targeted prevention, capacity planning for older adults, and long-term financing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Health Policy and Management, Nanjing Medical University, China (Y.J., M.X., M.C.).
- Healthcare Big Data Research Institute, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China (L.X.).
- The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, Australia (X.W.).
- School of Health Sciences, Faculty of Health, Western Sydney University, Campbelltown, New South Wales, Australia (L.S.).
- Translational Health Research Institute, Western Sydney University, Penrith, New South Wales, Australia (L.S.).
ORCID-Profile: Yutong Jiang, Lizheng Xu, Xia Wang, Meiqiyang Xue, Mingsheng Chen, Lei Si
Zitieren
APA
Jiang, Y., Xu, L., Wang, X., Xue, M., Chen, M., & Si, L. (2026). Projection of Stroke Incidence and Costs in China: 2022 to 2050. Stroke, 57(10), 3081-3090. https://doi.org/10.1161/strokeaha.125.054522
Vancouver
Jiang Y, Xu L, Wang X, Xue M, Chen M, Si L. Projection of Stroke Incidence and Costs in China: 2022 to 2050. Stroke. 2026;57(10):3081-3090. doi:10.1161/strokeaha.125.054522
BibTeX
@article{Jiang2026,
author = {Jiang, Yutong and Xu, Lizheng and Wang, Xia and Xue, Meiqiyang and Chen, Mingsheng and Si, Lei},
title = {Projection of Stroke Incidence and Costs in China: 2022 to 2050},
journal = {Stroke},
year = {2026},
volume = {57},
number = {10},
pages = {3081--3090},
doi = {10.1161/strokeaha.125.054522}
}
EUVIMED